Company news
Exelixis, Inc. (NASDAQ:EXEL) news
Exelixis, Inc. news releases on 6ix. Latest, Aug 31, 2026: Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
Press releases & updates
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
August 31, 2026
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
August 5, 2026
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
July 22, 2026
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
June 21, 2026
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
May 29, 2026
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
May 27, 2026
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
May 21, 2026
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
May 18, 2026
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
May 7, 2026
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
May 4, 2026
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026
April 21, 2026
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
February 24, 2026
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
February 10, 2026
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
February 1, 2026
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
January 27, 2026
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
January 10, 2026
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
January 6, 2026
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
January 5, 2026
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
December 2, 2025
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
November 5, 2025
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
November 3, 2025
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
October 20, 2025
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
October 19, 2025
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
October 17, 2025
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
September 16, 2025
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
August 28, 2025
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
August 26, 2025
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
July 27, 2025
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
July 23, 2025
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025
July 13, 2025
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
June 21, 2025
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
June 19, 2025
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June
May 21, 2025
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025
May 21, 2025
Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update
May 12, 2025
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
May 6, 2025
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
April 28, 2025
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
March 25, 2025
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
March 24, 2025
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
February 24, 2025
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
February 19, 2025
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
February 14, 2025
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
February 12, 2025
Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
February 10, 2025
Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
January 27, 2025
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025
January 24, 2025
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025
January 23, 2025
Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
January 11, 2025
Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
January 8, 2025
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
January 5, 2025